TP53 mutations and protein immunopositivity may predict for poor outcome but also for trastuzumab benefit in patients with early breast cancer treated in the adjuvant setting

George Fountzilas; Eleni Giannoulatou; Zoi Alexopoulou; Flora Zagouri; Eleni Timotheadou; Kyriaki Papadopoulou; Sotiris Lakis; Mattheos Bobos; Christos Poulios; Maria Sotiropoulou; Aggeliki Lyberopoulou; Helen Gogas; George Pentheroudakis; Dimitrios Pectasides; Αngelos Koutras; Christos Christodoulou; Christos N. Papandreou; Epaminontas Samantas; Pavlos Papakostas; P. Kosmidis; Dimitrios Bafaloukos; Charisios Karanikiotis; Meletios A Dimopoulos; Vassiliki Kotoula

doi:10.18632/oncotarget.9022

Shared by

Meletios A Dimopoulos

TP53 mutations and protein immunopositivity may predict for poor outcome but also for trastuzumab benefit in patients with early breast cancer treated in the adjuvant setting

Article 2016 en

Authors

GF
George Fountzilas
EG
Eleni Giannoulatou
ZA
Zoi Alexopoulou

Abstract

1 min read

TP53 mutations confer unfavorable prognosis in patients with Luminal A/B and TNBC tumors, while p53 immunopositivity may predict for trastuzumab benefit in the adjuvant setting.

Discussion(0)

No comments yet. Be the first to comment.

TP53 mutations and protein immunopositivity may predict for poor outcome but also for trastuzumab benefit in patients with early breast cancer treated in the adjuvant setting

Abstract

Discussion(0)

Related publications

Effect of mutant TP53 genotypes on the outcome of breast cancer (BC) patients in different clinical tumor subtypes.

Abstract P4-04-10: Clinically relevant tumor mutation profiles in patients with triple negative breast cancer (TNBC)

Long term survival of HER2-positive early breast cancer treated with trastuzumab-based adjuvant regimen: A large cohort study from clinical practice

The abundance of the long intergenic non-coding RNA 01087 differentiates between luminal and triple-negative breast cancers and predicts patient outcome

The Abundance of Long Intergenic Non-coding RNA 01087 Differentiates Luminal From Triple-negative Breast Cancer Patients and Predicts Their Clinical Outcome

Related publications

Article2015
Effect of mutant TP53 genotypes on the outcome of breast cancer (BC) patients in different clinical tumor subtypes.
Article2015

Article2013
Abstract P4-04-10: Clinically relevant tumor mutation profiles in patients with triple negative breast cancer (TNBC)
Article2013

Article2014
Long term survival of HER2-positive early breast cancer treated with trastuzumab-based adjuvant regimen: A large cohort study from clinical practice
Article2014

Article2020
The abundance of the long intergenic non-coding RNA 01087 differentiates between luminal and triple-negative breast cancers and predicts patient outcome
Article2020

Preprint2020
The Abundance of Long Intergenic Non-coding RNA 01087 Differentiates Luminal From Triple-negative Breast Cancer Patients and Predicts Their Clinical Outcome
Preprint2020